Skip to main content

Table 2 CGM parameters and urinary glucose level of 24 participants treated with SGLT2-I

From: Early effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: study based on continuous glucose monitoring

CGM parameters Before Day 0 Day 3 Day 7 p value
MBG, mg/dL 201.4 ± 55.6 180.8 ± 43.2* 154.0 ± 29.1* 142.3 ± 20.2* <0.001
SD, mg/dL 39.6 ± 13.5 34.7 ± 12.8 34.4 ± 12.8 31.7 ± 9.2* 0.006
CV, % 20.0 ± 5.5 19.1 ± 4.7 22.3 ± 6.7 22.6 ± 6.5 0.015
Time at >140 mg/dL, % 79.4 ± 24.7 74.7 ± 25.7 52.9 ± 25.6* 47.0 ± 23.7* <0.001
Time at <70 mg/dL, % 0 0 0.2 ± 1.1 0.9 ± 3.6 0.355
Time at 70–140 mg/dL, % 20.6 ± 24.7 25.3 ± 25.7 46.8 ± 25.5* 52.1 ± 22.8* <0.001
MAGE, mg/dL 106.9 ± 42.0 99.1 ± 38.8 96.3 ± 32.6 87.4 ± 25.2* 0.049
LAGE, mg/dL 147.5 ± 46.2 148.1 ± 51.0 132.9 ± 51.2 121.2 ± 38.3* 0.009
M value, mg/dL 47.7 ± 39.8 32.6 ± 27.1* 19.9 ± 15.2* 14.5 ± 6.7* <0.001
MPPGE, mg/dL 80.8 ± 30.6 76.8 ± 34.9 85.5 ± 35.2 79.3 ± 23.4 0.472
Max, mg/dL 282.4 ± 64.8 271.4 ± 66.1 237.3 ± 53.0* 217.3 ± 31.4* <0.001
Min, mg/dL 135.0 ± 43.9 123.3 ± 29.3 104.4 ± 19.4* 96.2 ± 22.1* <0.001
BGBB, mg/dL 176.5 ± 51.0 170.5 ± 37.5 135.2 ± 30.5* 121.9 ± 18.9* <0.001
BG1hAB, mg/dL 226.7 ± 56.7 207.4 ± 59.7 195.1 ± 38.9* 170.6 ± 28.6* <0.001
BG2hAB, mg/dL 249.8 ± 60.0 218.9 ± 67.5* 204.5 ± 48.6* 183.1 ± 36.9* <0.001
BGBL, mg/dL 206.5 ± 65.0 174.2 ± 60.6* 131.8 ± 39.8* 120.1 ± 25.6* <0.001
BG1hAL, mg/dL 241.1 ± 78.1 202.9 ± 65.9* 179.3 ± 41.5* 169.1 ± 33.8* <0.001
BG2hAL, mg/dL 229.8 ± 69.4 205.7 ± 67.6 182.5 ± 45.1* 171.4 ± 31.0* <0.001
BGBD, mg/dL 169.2 ± 59.4 142.3 ± 36.7* 125.5 ± 28.8* 121.1 ± 28.0* <0.001
BG1hAD, mg/dL 238.0 ± 68.0 204.6 ± 41.1* 192.7 ± 40.0* 183.1 ± 21.5* <0.001
BG2hAD, mg/dL 248.4 ± 72.8 217.8 ± 58.0* 205.7 ± 45.4* 187.7 ± 33.3* <0.001
Urinary glucose, g/day 18.8 ± 26.6   84.3 ± 31.9* 71.3 ± 31.7* <0.001
  1. Data are mean ± SD or n (%)
  2. Repeated measures ANOVA was used to determine the association-treatment difference
  3. CGM continuous glucose monitoring, SGLT2-I sodium glucose cotransporter 2 inhibitor, MBG mean blood glucose, SD standard deviation, CV coefficient of variation, MAGE mean amplitude of glycemic excursions, LAGE largest amplitude of glycemic excursions, MPPGE mean postprandial glucose excursions, BG blood glucose, BB before breakfast, AB after breakfast, BL before lunch, AL after lunch, BD before dinner, AD after dinner
  4. * p < 0.05 for differences with the value at before treatment